Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Nina Shah, MD

Recently, the FDA approved idecabtagene vicleucel (Abecma®, Bristol Myers Squibb) for patients with relapsed or refractory multiple myeloma who have already been treated with four or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval was based on KarMMa, a phase 2 trial that confirmed the efficacy and safety of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. In this interview, one of...
Continue reading

Understanding and Reducing Regional Variation in Prostate Cancer Surveillance: Samuel L. Washington III, MD, MAS

In patients with low-risk prostate cancer, the use of an active surveillance approach is significantly impacted by geographic location, according to a study recently published in JAMA Network Open. In this interview with i3 Health, Samuel L. Washington III, MD, MAS, Assistant Professor of Urology at the University of California San Francisco and the study's lead author, discusses the significance of these results and suggests ways to reduce variation in the use of active surveillance, thereby op...
Continue reading

Low-Risk Prostate Cancer: Active Surveillance Use Varies by Region

According to a recent cohort study, the use of active surveillance for low-risk prostate cancer is impacted by geographic location, despite a lack of association with Black race, the area's density of specialty physician's, or socioeconomic factors. "Active surveillance is now recognized as the preferred management option for most low-risk prostate cancers to minimize risks of overtreatment," write the investigators, led by first author Samuel L. Washington III, MD, MAS, an Assistant Professor o...
Continue reading

Margetuximab Plus Chemo Approved for HER2-Positive Breast Cancer

The FDA has now approved margetuximab-cmkb (MargenzaTM, MacroGenics) in combination with chemotherapy for adult patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least two prior anti-HER2 regimens. "HER2-targeting monoclonal antibodies are the standard of care in early-to-advanced HER2-positive breast cancer," write the authors of the phase 3 SOPHIA trial on which the approval was based, led by Hope S. Rugo, MD, Director of...
Continue reading

Thomas Hope, MD: Gallium 68 PSMA-11 Approval for PSMA-Targeted PET Imaging of Prostate Cancer

The FDA recently approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging of patients with recurrent prostate cancer. Ga 68 PSMA-11, the approval of which was granted to the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA), is the first agent to be approved specifically for the detection of PSMA-positive lesions. In this interview with i3 Hea...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.